Immunology Therapeutics
1. Ekterly patent expiration
Treatment: Treatment of acute attacks of hereditary angioedema (hae) in adults and pediatric patients 12 years of age and older
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US11084809 | KALVISTA | NA |
Nov, 2035
(9 years from now) | |
| US10364238 | KALVISTA | NA |
Nov, 2035
(9 years from now) | |
| US11001578 | KALVISTA | NA |
Nov, 2035
(9 years from now) | |
| US11230537 | KALVISTA | NA |
Dec, 2037
(11 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11198691 | KALVISTA | NA |
Nov, 2035
(9 years from now) | |
| US10611758 | KALVISTA | NA |
Nov, 2035
(9 years from now) | |
| US11739068 | KALVISTA | NA |
Jun, 2037
(11 years from now) | |
| US11234939 | KALVISTA | NA |
Jan, 2039
(13 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 03, 2030 |
Drugs and Companies using SEBETRALSTAT ingredient
NCE-1 date: 03 July, 2029
Market Authorisation Date: 03 July, 2025
Dosage: TABLET
More Information on Dosage
EKTERLY family patents
2. Firazyr patent expiration
Treatment: Treatment of pathological state by antagonizing bradykinin receptor including treatment of acute attacks of hereditary angioedema (hae)
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5648333 | TAKEDA PHARMS USA | Peptides having bradykinin antagonist action |
Jul, 2014
(11 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 25, 2016 |
| Orphan Drug Exclusivity(ODE) | Aug 25, 2018 |
| Orphan Drug Exclusivity(ODE-14) | Aug 25, 2018 |
Drugs and Companies using ICATIBANT ACETATE ingredient
NCE-1 date: 26 August, 2015
Market Authorisation Date: 25 August, 2011
Dosage: INJECTABLE
How can I launch a generic of FIRAZYR before it's drug patent expiration?
More Information on Dosage
FIRAZYR family patents
3. Jakafi patent
expiration
Treatment: For treatment of intermediate or high-risk myelofibrosis (mf), including primary mf, post-polycythemia vera mf and post-essential thrombocythemia mf; For treatment of steroid-refractory acute graft-ve...
JAKAFI's oppositions filed in EPO
JAKAFI IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9662335 | INCYTE CORP | Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as janus kinase inhibitors |
Dec, 2026
(11 months from now) | |
| US7598257 | INCYTE CORP | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors |
Dec, 2027
(1 year, 11 months from now) | |
| US8722693 | INCYTE CORP | Salts of the Janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile |
Jun, 2028
(2 years from now) | |
| US8415362 | INCYTE CORP | Pyrazolyl substituted pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors |
Dec, 2027
(1 year, 11 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8829013 | INCYTE CORP | Salts of the Janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-D]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile |
Jun, 2028
(2 years from now) | |
| US9079912 | INCYTE CORP | Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as Janus kinase inhibitors |
Dec, 2026
(11 months from now) | |
| US9814722 | INCYTE CORP | Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as janus kinase inhibitors |
Dec, 2026
(11 months from now) | |
| US10016429 | INCYTE CORP | Salts of the janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-D]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile |
Jun, 2028
(2 years from now) | |
| US8822481 | INCYTE CORP | Salts of the janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d] pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile |
Jun, 2028
(2 years from now) | |
|
US7598257 (Pediatric) | INCYTE CORP | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors |
Jun, 2028
(2 years from now) | |
|
US8415362 (Pediatric) | INCYTE CORP | Pyrazolyl substituted pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors |
Jun, 2028
(2 years from now) | |
|
US8722693 (Pediatric) | INCYTE CORP | Salts of the Janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile |
Dec, 2028
(2 years from now) | |
|
US8822481 (Pediatric) | INCYTE CORP | Salts of the janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d] pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile |
Dec, 2028
(2 years from now) | |
|
US8829013 (Pediatric) | INCYTE CORP | Salts of the Janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-D]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile |
Dec, 2028
(2 years from now) | |
|
US9079912 (Pediatric) | INCYTE CORP | Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as Janus kinase inhibitors |
Jun, 2027
(1 year, 5 months from now) | |
|
US9814722 (Pediatric) | INCYTE CORP | Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as janus kinase inhibitors |
Jun, 2027
(1 year, 5 months from now) | |
|
US10016429 (Pediatric) | INCYTE CORP | Salts of the janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-D]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile |
Dec, 2028
(2 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Nov 16, 2016 |
| New Indication(I-699) | Dec 04, 2017 |
| Orphan Drug Exclusivity(ODE) | Nov 16, 2018 |
| Orphan Drug Exclusivity(ODE-19) | Nov 16, 2018 |
| Orphan Drug Exclusivity(ODE-79) | Dec 04, 2021 |
| New Indication(I-799) | May 24, 2022 |
| New Indication(I-872) | Sep 22, 2024 |
| M(M-285) | Dec 19, 2025 |
| Orphan Drug Exclusivity(ODE-238) | May 24, 2026 |
| Orphan Drug Exclusivity(ODE-373) | Sep 22, 2028 |
| Pediatric Exclusivity(PED) | Mar 22, 2029 |
Drugs and Companies using RUXOLITINIB PHOSPHATE ingredient
NCE-1 date: 22 March, 2028
Market Authorisation Date: 16 November, 2011
Dosage: TABLET
How can I launch a generic of JAKAFI before it's drug patent expiration?
More Information on Dosage
JAKAFI family patents
4. Joenja patent expiration
Treatment: NA
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8653092 | PHARMING | Tetrahydro-pyrido-pyrimidine derivatives |
Feb, 2032
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Mar 24, 2028 |
| Orphan Drug Exclusivity(ODE-430) | Mar 24, 2030 |
Drugs and Companies using LENIOLISIB PHOSPHATE ingredient
NCE-1 date: 25 March, 2027
Market Authorisation Date: 24 March, 2023
Dosage: TABLET
More Information on Dosage
JOENJA family patents
5. Orladeyo patent expiration
Treatment: Prophylaxis to prevent attacks of hereditary angioedema (hae) in adult and pediatric patients 12 years of age and older; Prophylaxis to prevent attacks of hereditary angioedema (hae) in adults and ped...
Can you believe ORLADEYO received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US10125102 | BIOCRYST | Human plasma kallikrein inhibitors |
Apr, 2035
(9 years from now) | |
| US10662160 | BIOCRYST | Crystalline salts of a plasma kallikrein inhibitor |
Nov, 2039
(13 years from now) | |
| US12116346 | BIOCRYST | Human plasma kallikrein inhibitors |
Mar, 2035
(9 years from now) | |
| US10329260 | BIOCRYST | Human plasma kallikrein inhibitors |
Mar, 2035
(9 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11117867 | BIOCRYST | Crystalline salts of a plasma kallikrein inhibitor |
Nov, 2039
(13 years from now) | |
| US11230530 | BIOCRYST | Human plasma kallikrein inhibitors |
Mar, 2035
(9 years from now) | |
| US11708333 | BIOCRYST | Human plasma kallikrein inhibitors |
Mar, 2035
(9 years from now) | |
| US12344585 | BIOCRYST | NA |
Nov, 2039
(13 years from now) | |
| US10689346 | BIOCRYST | Human plasma kallikrein inhibitors |
Mar, 2035
(9 years from now) | |
| US11618733 | BIOCRYST | Crystalline salts of a plasma kallikrein inhibitor |
Nov, 2039
(13 years from now) | |
|
US12344585 (Pediatric) | BIOCRYST | NA |
May, 2040
(14 years from now) | |
|
US11618733 (Pediatric) | BIOCRYST | NA |
May, 2040
(14 years from now) | |
|
US12116346 (Pediatric) | BIOCRYST | NA |
Sep, 2035
(9 years from now) | |
|
US11117867 (Pediatric) | BIOCRYST | NA |
May, 2040
(14 years from now) | |
|
US11708333 (Pediatric) | BIOCRYST | NA |
Sep, 2035
(9 years from now) | |
|
US11230530 (Pediatric) | BIOCRYST | NA |
Sep, 2035
(9 years from now) | |
|
US10125102 (Pediatric) | BIOCRYST | NA |
Oct, 2035
(9 years from now) | |
|
US10689346 (Pediatric) | BIOCRYST | NA |
Sep, 2035
(9 years from now) | |
|
US10662160 (Pediatric) | BIOCRYST | NA |
May, 2040
(14 years from now) | |
|
US10329260 (Pediatric) | BIOCRYST | NA |
Sep, 2035
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 03, 2025 |
| Orphan Drug Exclusivity(ODE-333) | Dec 03, 2027 |
| Pediatric Exclusivity(PED) | Jun 03, 2028 |
Drugs and Companies using BEROTRALSTAT HYDROCHLORIDE ingredient
NCE-1 date: 04 June, 2027
Market Authorisation Date: 03 December, 2020
Dosage: CAPSULE
More Information on Dosage
ORLADEYO family patents
6. Rapamune patent expiration
Treatment: Inhibiting transplant rejection using rapamycin (sirolimus)
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5536729 | PF PRISM CV | Rapamycin formulations for oral administration |
Sep, 2013
(12 years ago) | |
| US5100899 | PF PRISM CV | Methods of inhibiting transplant rejection in mammals using rapamycin and derivatives and prodrugs thereof |
Jul, 2013
(12 years ago) | |
| US5989591 | PF PRISM CV | Rapamycin formulations for oral administration |
Mar, 2018
(7 years ago) | |
|
US5536729 (Pediatric) | PF PRISM CV | Rapamycin formulations for oral administration |
Mar, 2014
(11 years ago) | |
|
US5100899 (Pediatric) | PF PRISM CV | Methods of inhibiting transplant rejection in mammals using rapamycin and derivatives and prodrugs thereof |
Jan, 2014
(12 years ago) | |
|
US5403833 (Pediatric) | PF PRISM CV | Methods of inhibiting transplant rejecton in mammals using rapamycin and derivatives and prodrugs thereof |
Oct, 2012
(13 years ago) | |
|
US5989591 (Pediatric) | PF PRISM CV | Rapamycin formulations for oral administration |
Sep, 2018
(7 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE) | May 28, 2022 |
| Orphan Drug Exclusivity(ODE-92) | May 28, 2022 |
Drugs and Companies using SIROLIMUS ingredient
Market Authorisation Date: 15 September, 1999
Dosage: SOLUTION; TABLET
How can I launch a generic of RAPAMUNE before it's drug patent expiration?
More Information on Dosage
RAPAMUNE family patents
7. Tavneos patent expiration
Treatment: An adjunctive treatment of adult patients with tavneos (avacopan) with severe active anca-associated vasculitis (gpa and mpa) in combination with standard therapy including glucocorticoids
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US11603356 | CHEMOCENTRYX | Amorphous form of a complement component C5a receptor |
May, 2041
(15 years from now) | |
| US8906938 | CHEMOCENTRYX | C5aR antagonists |
Dec, 2029
(3 years from now) | |
| US8445515 | CHEMOCENTRYX | C5aR antagonists |
Feb, 2031
(5 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11951214 | CHEMOCENTRYX | Capsule formulations |
Nov, 2039
(13 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 07, 2026 |
| Orphan Drug Exclusivity(ODE-377) | Oct 07, 2028 |
Drugs and Companies using AVACOPAN ingredient
NCE-1 date: 07 October, 2025
Market Authorisation Date: 07 October, 2021
Dosage: CAPSULE
More Information on Dosage
TAVNEOS family patents
8. Xolremdi patent expiration
Treatment: Treatment of patients 12 years and older with warts, hypogammaglobulinemia, infections, and myelokathexis (whim) syndrome
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11219621 | X4 PHARMS | Methods for treating immunodeficiency disease |
Dec, 2036
(10 years from now) | |
| US10610527 | X4 PHARMS | Methods for treating immunodeficiency disease |
Dec, 2036
(10 years from now) | |
| US11045461 | X4 PHARMS | Compositions of CXCR4 inhibitors and methods of preparation and use |
Dec, 2038
(12 years from now) | |
| US10953003 | X4 PHARMS | Methods for treating cancer |
Dec, 2036
(10 years from now) | |
| US12115156 | X4 PHARMS | Compositions of CXCR4 inhibitors and methods of preparation and use |
Dec, 2038
(12 years from now) | |
| US10548889 | X4 PHARMS | Compositions of CXCR4 inhibitors and methods of preparation and use |
Dec, 2038
(12 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Apr 26, 2029 |
| Orphan Drug Exclusivity(ODE-480) | Apr 26, 2031 |
Drugs and Companies using MAVORIXAFOR ingredient
NCE-1 date: 26 April, 2028
Market Authorisation Date: 26 April, 2024
Dosage: CAPSULE
More Information on Dosage
XOLREMDI family patents